Emilia Quattrocchi
Marlow, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Safety, tolerability, pharmacokinetics, and efficacy of burosumab in infants with X-linked hypophosphataemia: an open-label, multicentre, non-randomised study.
Journal: The lancet. Diabetes & endocrinology
Published: August 15, 2025
Pharmacodynamic Exposure-Response Analysis of Fracture Count Data Following Treatment with Burosumab in Patients with XLH.
Journal: Journal of clinical pharmacology
Published: June 25, 2024
Model-Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor-Induced Osteomalacia.
Journal: Clinical pharmacology and therapeutics
Published: May 14, 2024
Item Response Theory Quantifies the Relationship Between Improvements in Serum Phosphate and Patient-Reported Outcomes in Adults With X-Linked Hypophosphatemia.
Journal: Clinical pharmacology and therapeutics
Published: February 14, 2024
A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis.
Journal: Arthritis research & therapy
Published: October 21, 2020
Using a ResearchKit Smartphone App to Collect Rheumatoid Arthritis Symptoms From Real-World Participants: Feasibility Study.
Journal: JMIR mHealth and uHealth
Published: December 14, 2017
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
Journal: PloS one
Published: December 22, 2015
Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
Journal: Arthritis care & research
Published: November 21, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026